Soley Therapeutics closed a $200 million Series C to advance its stress‑sensing drug discovery platform and push lead oncology candidates toward IND filings and clinic entry. The company cited broad application of its approach across cancer, neurodegeneration and metabolic disease. Separately, Proxima (formerly VantAI) raised $80 million in an oversubscribed seed round to develop AI‑driven proximity‑modulating drugs that target protein interactions. Proxima said it will pair proteome‑scale structural data with frontier AI models to design proximity‑based therapeutics across cancer and immunology. Both financings reflect investor appetite for platform biotechs tackling hard biology with AI or novel mechanistic hypotheses. Expect both firms to accelerate preclinical programs and to seek pharma partnerships or further rounds as they approach clinical inflection points.